StockpollyBeta
Get App
Popularity #3,331
MESO · NASDAQ · Biotechnology

Mesoblast (ADR) (MESO)

Develops FDA-approved Ryoncil for pediatric steroid-refractory acute graft-versus-host disease.

$15.35
vs last close−0.57 (−3.58%)

In millions of USD, except per-share figures

In millionsQ1 FY24Sep 2023Q2 FY24Dec 2023Q3 FY24Mar 2024Q4 FY24Jun 2024Q1 FY25Sep 2024Q2 FY25Dec 2024Q3 FY25Mar 2025Q4 FY25Jun 2025Q1 FY26Sep 2025Q2 FY26Dec 2025Q3 FY26Mar 2026Q4 FY26Jun 2026
Revenue2211227726263435
Cost of revenue10101111332323272715−49
Gross profit−8−8−10−10−2−2−16−16−1−14949
121212121919181837374040
Research & development666610107723232626
666699111114141414
Selling & marketing001100220000
General & administrative665599990000
Operating income−20−20−22−22−21−21−34−34−39−39−20−20
44−6−6−3−3771919120
Interest income000000−4−40000
Interest expense554455006600
Other non-operating income776−6−11−11−13−13−24−24−9−9
Income before tax−16−16−28−28−24−24−27−27−20−20−9−9
Income tax expense000000000000
Net income from continuing operations−16−16−28−28−24−24−27−27−20−20−9−9
Net income−16−16−28−28−24−24−27−27−20−20−9−9
EPS, basic−$0.19−$0.19−$0.25−$0.25−$0.21−$0.21−$0.21−$0.21−$0.15−$0.15−$0.07−$0.07
EPS, diluted−$0.19−$0.19−$0.25−$0.25−$0.21−$0.21−$0.21−$0.21−$0.15−$0.15−$0.07−$0.07
Weighted average shares, basic8585112112114114127127129129130130
Weighted average shares, diluted8585112112114114127127129129130130
EBITDA−13−13−15−15−9−9−20−20−13−13−10−10
Depreciation & amortization110011222211
EBIT−13−13−16−16−10−10−21−21−14−14−11−11